Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, November 30, 2010

Investor Video; BioSante (NASDAQ: BPAX) Presentation at Cancer Immunotherapy Conference BioSante Pharmaceutical’s President and CEO Discusses BioSante Portfolio of Cancer Vaccines

Point Roberts, WA, LINCOLNSHIRE, Ill - November 30, 2010 (Investorideas.com Newswire) Invest orideas.com, an investor research portal specialized in sector investing including biotech and pharma stocks, features an investor video featuring showcase company BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
The video, featuring Stephen M. Simes, President and CEO, was recorded during "Cancer Immunotherapy: A Long Awaited Reality", a conference hosted by BioBusiness.TV and MD Becker Partners on October 21st, 2010, at the New York Academy of Medicine. Mr. Simes discusses the GVAX wide portfolio of cancer vaccines.
Mr. Simes reports, "There are fifteen BioSante cancer vaccine Phase I and Phase II studies ongoing in different cancers."
Watch BioSante's segment on Cancer Vaccines for the Cancer Immunotherapy Conference the following link is provided: http://www.biobusiness.tv/report-on-location/biosante-presentation-at-cancer-immunotherapy-conference-1548/
Highlights from the Cancer Vaccines Product Page:
Read the Full info at: http://www.biosantepharma.com/Cancer-Vaccines.php
BioSante Pharmaceuticals Inc. is developing a pipeline of Immunotherapies (cancer vaccines). BioSante's cancer vaccines use cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immunostimulant. The cells then are irradiated to prevent further cell division; however the cells remain metabolically active.
Currently, BioSante's Cancer Vaccines are in various Phase I and Phase II cancer clinical trials and may represent the widest portfolio (cancer types) of cancer vaccines in development. Studies are conducted primarily at Johns Hopkins Cancer Center and are sponsored/funded by The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, various philanthropies, foundations and the National Cancer Institute
Cancer Types Being Studied:
  • Leukemia
  • Chronic Myeloid Leukemia (CML)
  • Acute Myeloid Leukemia (AML)
  • Pancreatic Cancer
  • Breast Cancer
  • Multiple Myeloma
  • Melanoma
  • Colorectal
  • Prostate Cancer
Chronic Myeloid Leukemia (CML) — Results of a Phase II clinical trial
Of 19 patients treated with GVAX CML, 7 had complete remission.
  • Gleevec was taken for at least one year (range 13-53 months) pre-vaccine and then GVAX CML was administered while the patients remained on a stable dose of Gleevec.
  • 19 patients enrolled (median of 72 months of follow-up)
  • 13 patients (8 of whom had increasing disease burden before vaccination): the number of remaining cancer cells declined
  • 12 patients reached their lowest levels of residual cancer cells to date following vaccination
  • 7 patients had complete remission
"We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a good way to mop up residual disease," said lead investigator Hyam Levitsky, M.D., professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland.
Acute Myeloid Leukemia (AML) — Results of Phase II
Patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects.
  • GVAX AML was accompanied by immunotherapy-primed lymphocytes after autologous stem cell transplantation.
  • 54 subjects enrolled
  • 28 (52%) received a pre-transplantation GVAX AML dose
  • 46 (85%) subjects achieved complete remission during the treatment period. Of these patients, the 3-year relapse-free survival (RFS) rate was:
    • 47.4% in non-GVAX treated patients
    • 61.8% in the GVAX-treated group
    • Overall survival (OS) rate in all subjects was 57.4%
    • Overall survival (OS) rate was 73.4% in the GVAX-treated group
    • In summary, patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects
Read more on BioSante's Cancer Vaccines and clinical trial info at: http://www.biosantepharma.com/Cancer-Vaccines.php
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal : www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer:
The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Urgent Health Threat from Airborne Viruses; How UV Flu Technologies, Inc. (OTCBB: UVFT innovative new air purification technology is more effective than filtering

Point Roberts WA - November 30, 2010 – www.Investorideas.com, an investor research portal
specialized in sector investing, issues biotech stocks commentary by Lisa Springer, CFA, equity
research analyst and financial writer. The report entitled,’ Urgent Health Threat from Airborne
Viruses ‘, features UV Flu Technologies, Inc. (OTCBB: UVFT) and its air purification technology.

Urgent Health Threat from Airborne Viruses

Lisa Springer, CFA, Equity research analyst and financial writer

Stocks in this report: UV Flu Technologies, Inc. (OTCBB: UVFT), Pall Corp (NYSE:PLL),
Donaldson Company (NYSE:DCI)

There is an urgent health threat deadlier than the H1N1 pandemic on the rise, yet few Americans
are aware of it. The threat comes from infections acquired while in the hospital. According to a
recent government study, America’s hospitals aren’t adequately protecting patients from these
potentially deadly infections. A 2009 report by the US Health and Human Services department
found little progress has been made over the past decade in eliminating hospital-acquired
infections and urged Congress to take action.

As many as 98,000 Americans die each year from medical errors and preventable infections are
a major contributor to the problem. Ten years ago, the Institute of Medicine launched a campaign
to stamp out hospital-acquired infections, but the success of their initiatives has been minimal.
The latest report showed three of five major types of hospital-acquired infections have actually
become more prevalent, one showed no progress and only one declined. Bloodstream infections,
which are considered the most serious and potentially fatal, rose 8.0 percent. There was also
a sizable 3.6 percent increase in the incidence of urinary tract infections. While generally
responsive to antibiotics, urinary tract infections increase hospitalization time and costs. Overall,
the incidence of common hospital-acquired infections was up 1.6 percent.

Media coverage of hospital-acquired infections, the swine flu pandemic and antibiotic resistant
superbugs is raising consumer awareness and spurring government agencies and businesses
to take action to safeguard public health. Demand for products that prevent the spread of
airborne illnesses is rising exponentially. The swine flu pandemic created a $7 billion windfall for
vaccine manufacturers, according to the Wall Street Journal, and a bonanza for makers of hand
sanitizers, who experienced a 129% jump in shipments during last year’s flu season.
This heightened awareness is also spreading to the nearly $8 billion annual market for indoor air
quality products. These products improve air quality in commercial buildings, hospitals, schools
and homes by removing airborne pathogens. Scientific studies show poor indoor air quality is
a major reason for the spread of infectious disease. According to the Environmental Protection
Agency, the air inside buildings where people spend 90% of their time now poses a greater threat
than outdoor air.

Most air quality systems use a simple filter (either standard or HEPA) to trap pathogens.
Well-known filter device manufacturers include Pall Corp (NYSE:PLL), Donaldson Company
(NYSE:DCI) and Millipore, which was recently acquired by Merck KGaA. A relative newcomer
to this market, UV Flu Technologies, Inc. (OTCBB: UVFT), has developed an innovative new air
purification technology that is more effective than filtering. This technology disinfects indoor air
by deactivating allergens and killing airborne pathogens, including bacteria, viruses and mold.
UV Flu Technologies flagship product, the ViraTech UV-400, uses high intensity germicidal UV
radiation inside a killing chamber to trap and destroy harmful microbes. Extensive independent
testing by EPA and FDA certified laboratories confirms UV Flu Technologies system captures and

kills airborne bacteria and viruses at rates exceeding 99.2% on a first pass basis. The technology
is so effective that UV Flu Technologies was able to secure a Class II medical listing enabling it to
market its product as a medical device.

Since introducing its flagship device less than one year ago, UV Flu Technologies has sold
units to multiple sports teams, hospitals, restaurants and other commercial customers. Two
professional hockey teams (including the renowned Boston Bruins) and numerous college
teams have installed ViraTech UV-400 units in their locker rooms. In addition, the company has
installed units at two major hospitals and has units being evaluated by a large nursing home
chain. Hospitality customers such as The Seagate Hotel and Spa in Delray Beach, Florida, the
Boston Harbor Hotel and Boston’s XV Beacon Hotel have installed ViraTech UV-400 units and
one of the nation's largest 5 star hotels is evaluating the unit for its operations. Tests of units
are also underway with one of the largest hotel and restaurant suppliers in the Northeast. In
addition, "Clean Air for Everyone," a non-profit promoting clean air for schools and non-profits
across America recently selected the ViraTech UV-400 as its lead product for national rollout.

UV Flu Technologies plans to expand its product line and distribution capabilities by acquiring
a major US manufacturer of high quality air purification equipment. The company hopes to
complete the merger this year. Included in the agreement is a patented product line, national
distribution network, and installed base of several thousand units across 1,000 unique facilities
nationwide. UVFT President Jack Lennon notes that the expanded product line will make the
company more attractive to large US distributors and improve its visibility in the hospital, hotel
and casino markets. UV Flu Technologies is also expanding its sales channels by adding three
new distributors. The new distributors are Emerald Medical Service, a supplier of medical
equipment serving the Washington, DC area; UV Air, a supplier to government, schools,
and hotels in Massachusetts and Factory-Direct Green, a distributor servicing over 400 hotel
customers in California.

Lisa Springer, CFA -Bio and disclaimer: http://www.investorideas.com/About/Lisa-Springer-CFA/

The author, Lisa Springer, was compensated for writing this article and doesn't own shares of any
of the companies mentioned in this article.

About UV Flu Technologies, Inc. (OTCBB: UVFT)

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology
products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over
$7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-
intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to
destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also
reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone,
benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables
UV Flu Technologies to market the product as a medical device. For more information, visit:
www.uvflutech.com. For sales: www.puravair.com.
Read the forward looking statements disclaimer on all company press releases and company
website.

UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

UV Flu Technologies, Inc.

Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including biotech stocks.
Research more biotech stocks at the Biotech stocks Directory:
http://www.investorideas.com/BIS/Stock_List.asp

Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc.,
(three thousand per month) Lisa Springer CFA- Investorideas compensated three hundred fifty
for article. Investorideas.com is a third party publisher of news and research .Our sites do not
make recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. This site is currently compensated by featured companies, news
submissions and online advertising.

Contact Investorideas.com
cvanzant@investorideas.com 800 665 0411

Monday, November 29, 2010

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Highlights 2010 Operations as ViraTech UV-400 Is Selected as Product of Choice by National Clean Air Foundation

CENTERVILLE, MA � November 29, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), manufacturers of innovative air purification technology, announced today that the Company has been informed by one of its distributors, INE Global, of Boston, Mass, that "Clean Air for Everyone," a national non-profit promoting clean air for schools and non-profits around the Country, has selected the ViraTech UV-400 as the lead product to be distributed throughout America.
"This product can help our schools, and the children within them," said John Pappas, spokesperson for 'Clean Air for Everyone.' "There are thousands of schools, homeless shelters, and Aids clinics around the country, that suffer through horrific air quality, due to the lack of funding to correct or improve the situation. The UV-400 kills the bacteria, odors, VOCs, and other organic contaminants that cause sickness, respiratory problems, and allergies that make our children ill."
The announcement of this news now positions UV Flu Technologies across a multitude of operational initiatives and industry segments including:
Sports and Athletics - Announced an order of UV-400 units in the locker room of the renowned Boston Bruins hockey team. "This is the second professional hockey team to put the UV-400 in their locker rooms, along with numerous colleges," noted Charles Gulteri President of New England Sports Sales (NESSI). "This could be one of the most important developments to college and professional sports in the last 20 years."
Healthcare and Medical - Units have been utilized in 2 major hospitals, and are currently being evaluated by a major nursing home chain. Units placed with the prestigious Miami Anatomical Research Center featuring 40 state-of-the art bio-skill lab stations in a hospital style setting.
Hospitality, Hotel & Spa - The Seagate Hotel and Spa in Delray Beach, Florida, the Boston Harbor Hotel, and Boston's XV Beacon Hotel utilize the ViraTech UV-400. "Providing this extra level of protection sets us apart from the competition," said William Sander, GM of the Seagate Hotel. UV Flu announced a new hospitality initiative branded ABC ROOMS, representing guest rooms and public areas treated for Allergens/Bacteria/and Contaminants. One of the nation's largest 5 star hotels is currently evaluating the unit for all areas of its operation.
European Market - Profiled in two editions (July and October) of the prestigious UK industry opinion and analysis publication "The Public Service Review" featuring the latest initiatives and projects on best practices affecting public sector initiatives worldwide. This announcement was followed almost immediately by a sales order with Paris based, Societe Nema Citizen, the largest distributor of Citizen Brand electronics in France, and a growing inventory of health and medical-related products sold throughout Western Europe.
Restaurants - The ViraTech UV-400 is undergoing testing supervised by one of the largest hotel and restaurant suppliers in the Northeast. The unit is being evaluated in the lounge, dining, and food prep areas of 3 notable NYC restaurants. The product's ability to reduce odors, VOCs, while killing bacteria and other contaminants, is drawing considerable attention in this segment.
Industrial and Commercial - UV Flu announced a Letter of Intent ("LOI") to acquire 100% of the ownership of a major US manufacturer of high quality industrial air purification equipment specializing in the medical and hospitality marketplace. The agreement includes a patented, trademarked product line, with dozens of national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The company's sales include an installed base of several thousand units in over 1000 unique facilities nationwide.
National Distribution Network - The Company added 3 new distributors including Emerald Medical Service, a supplier of medical equipment throughout the Washington, DC area, UV Air, a supplier to government, schools, and hotels in the Woburn, MA area, and Factory-Direct Green, a distributor servicing over 400 hotel customers in the Carlsbad, California area.
New Research - Received favorable preliminary test results from independent FDA and EPA certified test facilities that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol. If advanced stage testing proves positive, this could be a momentous step forward in the further development of the product as a Medical Device.
Television - UV Flu Technologies invites everyone to visit the Company website (www.uvflutech.com) to view an informative, seasonal video presented by the producers of the TV show, "Designing Spaces" which highlights the features and benefits of the UV-400 especially during the Holiday Season.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Friday, November 26, 2010

Air Purifier Stocks Close-Up; UV Flu Technologies (OTCBB: UVFT), Lennox (NYSE: LII), Sharp (TYO: 6753), SEUNG CHANG (KOSDAQ: 080470.KQ)

Point Roberts WA - November 26 (Investorideas.com Newswire) Investorideas.com, a leader in sector research for independent investors, reports on publicly traded stocks in the air purifier market.
Sector snapshot – stocks in the air purifier market
  • Clean & Science (KOSDAQ: 045520.KQ)
  • Lennox International, Inc. (NYSE: LII )
  • SEUNG CHANG (KOSDAQ: 080470.KQ)
  • Sharp (TYO: 6753)
  • Sharper Image Corp. (SHRPQ.PK)
  • UV Flu Technologies, Inc. (OTCBB: UVFT)
Plasmacluster air purifier is designed in Japan by Sharp, a global leader in microelectronics. Sharp's shares are listed on Tokyo, Osaka, Nagoya, Fukuoka and Sapporo in Japan, securities code 6753.
According to an article in air-purifier-power.com, "The purifier market is rapidly consolidating, with many small players disappearing."
http://www.air-purifier-power.com/sharp-air-purifier.html
Lennox International, Inc. (NYSE: LII ) residential Heating & Cooling manufactures and markets a full line of home heating and cooling equipment: furnaces, air conditioners, heat pumps, fireplaces and hearth products, as well as a variety of accessories to improve indoor air quality including humidifiers and electronic air cleaners.
Clean & Science Co., Ltd. (KOSDAQ: 045520.KQ) is a Korea-based manufacturer engaged in the provision of value-added materials for filters. The Company provides its products under three main categories: automotive filter media, which is used as core component in air, oil and fuel filters; industrial filter media, which is used in the gas turbine air filters, cutting filters, dry-cleaning filters and compressor filters, and melt blown, which is used in ventilation and air conditioning filters, high efficiency particulate air (HEPA) filters, medical equipment, water purifiers, industrial masks and others. The Company also manufactures filters such as air cleaner filters, air conditioner filters and gas turbines filters.
Recent Air Purifier Stock News;
UV Flu Technologies (OTCBB: UVFT) Identifies New Prospects for UV-400 Air Purifier With Rising Health Concerns Within Hospitality Market Segments
CENTERVILLE, MA - November 17, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), announced today that the Company is expanding its focus within the Hospitality industry to newly identified areas suffering from serious health concerns for both customers and employees alike. Commencing immediately, the Company will direct efforts to provide its UV-400 air quality solution targeting the restaurant and spa sectors.
Restaurants generally prove vulnerable to poor indoor air quality, particularly with respect to the use of cleaning solvents in the dining room and bar areas, as well as the possibility for odors, mold and mildew that can plague food preparation areas. Full news: http://www.investorideas.com/CO/UVFT/news/11171.asp
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at: http://www.investorideas.com/CO/UVFT/
Research Report by Michael Williams, Biotech Stock Pick: www.biotechstockpick.com
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at: www.uvflutech.com
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
http://www.investorideas.com/Resources/Newsletter.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory:
http://www.investorideas.com/BIS/Stock_List.asp

Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com

Wednesday, November 17, 2010

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) sells virus technology to Cold Genesys

LINCOLNSHIRE, Ill. - November 17, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) said Wednesday it sold rights to develop and commercialize its oncolytic virus technology to Cold Genesys Inc. for $95,000 and a nearly 20 percent ownership stake in that company.
BioSante, based in Lincolnshire, Ill., also can receive future milestone and royalty payments.
Oncolytic virus therapy uses a virus that causes colds to attack cancer cells. The adenoviruses are engineered to replicate inside targeted cancer cells to kill them and leave healthy cells largely unharmed.
Technology sold to Cold Genesys includes CG0070, an adenovirus that finished early-stage clinical testing for the treatment of superficial bladder cancer.
Cold Genesys, based in Newport Beach, Calif., is a privately-funded specialty pharmaceutical company that currently is focused on finding treatments for bladder cancer.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
For more information, please contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Identifies New Prospects for UV-400 Air Purifier With Rising Health Concerns Within Hospitality Market Segments

CENTERVILLE, MA � November 17, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), announced today that the Company is expanding its focus within the Hospitality industry to newly identified areas suffering from serious health concerns for both customers and employees alike. Commencing immediately, the Company will direct efforts to provide its UV-400 air quality solution targeting the restaurant and spa sectors.
Restaurants generally prove vulnerable to poor indoor air quality, particularly with respect to the use of cleaning solvents in the dining room and bar areas, as well as the possibility for odors, mold and mildew that can plague food preparation areas.
In the personal grooming arena, Spas and Salons across the Country have demonstrated increasing evidence of illnesses affecting employees, customers, and even children due to the presence of Volatile Organic Compounds ("VOC") emitted by a variety of hair, nail and other personal grooming treatments, in many instances with little or no air purification whatsoever provided.
"There are serious ramifications building across the Country due to the lack of education on how damaging these contaminants are to the long term health of the people that are breathing them on a regular basis," said Jack Lennon, President of UV Flu Technologies. "We are contacted on a weekly basis by parents, as well as workers and customers, who have experienced symptoms of illness themselves, or whose children have experienced negative effects while certain treatments were underway with no air purification in evidence, or with non-functioning air purifiers being used."
"A particularly troubling aspect is that many of these individuals breathing these VOC's are at young ages critical to the development of their heart and lungs," continues Mr. Lennon, "Some of these popular hair treatments have been shown recently to contain up to 20% formaldehyde, while acetone and benzene are being used for nails. These contaminants are known carcinogens, and salons who are not addressing the concerns of their employees and customers are not only facing a loss of business, but the risk of litigation, as well as potential legislation."
Mr. Lennon continues, "Regarding the several-hundred thousand restaurants in this country, we believe that up to one in four restaurants suffers to a degree from odors caused by cleaning solvents, and in such a competitive marketplace it doesn't take much to adversely affect a business in an area that has already been severely hurt by the decline of the domestic economy. If people smell chemicals when they dine out, they may leave, or choose not to return... and in many instances it's a subliminal decision. In the food prep area there are many opportunities due principally to moisture that can affect the build-up of odors, mold and mildew. Good food preparation procedures alone can't prevent these types of air quality issues which ultimately could not only hurt the reputation of the business, but in extreme cases, cause its closure."
"Our air purifier, the ViraTech UV-400, reduces all types of odors and Volatile Organic Compounds, while also killing bacteria and other contaminants. The unit could potentially pay for itself in its first day of operation in many instances. We think from the standpoint of return on investment, as well an obligation to keep their employees and customers healthy and safe, this is a must-buy product," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Tuesday, November 16, 2010

Biotechnology Company UV Flu Technologies (OTCBB: UVFT) Air Purifier is the "Star of the Show" on Designing Spaces

Holiday Health Segment features Biotechnology product from UV Flu
Technologies (OTCBB: UVFT)

Point Roberts, WA, LINCOLNSHIRE, Ill –November 16, 2010 (Investorideas.com Newswire)
Investorideas.com reports that showcase biotech stock UV Flu Technologies (OTC.BB: UVFT)
is the “Star of the Show “on the Designing Spaces, Holiday Spaces – ‘Innovations for a Healthy
Home this Holiday Season’ segment.

Designing Spaces host Debi Marie interviews J. Lennon, President and CEO of UV Flu
Technologies (OTCBB: UVFT), along with pediatrician Dr. Dennis J. Rosen. The segment
discusses how UV Flu Technologies lead product, UV-400 Air Purifier, is an added and important
health measure to keep holiday colds and flu’s out of the house during the busy social season.

Interested investors and consumers can watch the UV Flu Technologies segment on
Designing Spaces at http://www.designingspaces.tv/show_segment.php?id=732 or at
the company’s website http://www.uvflutech.com/

During the holidays, families and friends look forward to spending time together. The one thing
they might not look forward to is that along with the company, you may be inviting unwelcomed
cold and flu germs as well! UV FLU Technologies, Inc. offers an innovative way to help deter the
unwanted holiday bugs. More: http://www.designingspaces.tv/show_segment.php?id=732

About UVFT.OB: UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer,
manufacturer and distributor of bio technology products initially targeting the rapidly growing
Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400,
which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that
goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-
pass basis. VIRATECH UV-400 is a Class II medical device and is available

Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Get added to the company’s news alerts :
http://www.investorideas.com/Resources/Newsletter.asp

UV Flu Technologies (OTC.BB: UVFT) recent news;

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Announces UV-400
Air Purifier Delivers Favorable Preliminary Test Results for the Inactivation of Viruses

CENTERVILLE, MA – November 11, 2010 (Investorideas.com Newswire) - UV Flu Technologies,
Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has received
favorable preliminary test results from an independent, FDA and EPA certified test facility that
demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus
surrogate utilized as part of the test protocol.

"These results, although preliminary, are highly encouraging," said Jack Lennon, President of
UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at
three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test
chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over
all three speeds, which was shown to be even higher at the four hour mark. We must emphasize

that these results, although very positive, are only preliminary, but appear comparable to our
previous results during the laboratory testing of the inactivation of bacteria. Our Company is
firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by
reputable agencies within certified facilities."
Full News at: http://www.investorideas.com/CO/UVFT/news/11111.asp

Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com

Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.

Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per
month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations,
but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured
companies, news submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Contact Investorideas.com
cvanzant@investorideas.com 800 665 0411

Investor Video Airing for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) November 20th

BioSante Pharmaceutical’s President and CEO to be featured on WallStreetCast
on ‘Fox Business with Steve Crowley’, Saturday at 1 pm EST

Point Roberts, WA, LINCOLNSHIRE, Ill –November 16, 2010 (Investorideas.com Newswire)
Investorideas.com announces to interested biotech and pharmaceutical investors following
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) that the company will be featured in an
upcoming video segment November 20th.

Saturdays airing will feature Mr. Stephen Simes, President and CEO of BioSante, discussing
BioSante’s lead products, including LibiGel®, with host Steve Crowley.

For interested investors looking to watch BioSante’s segment, the show will be aired on
WallStreetCast on Fox Business on Saturday, November 20th at 1 PM EST

Investors can also go to the Money Channel at, http://www.moneychannel.tv/ to find times aired
and to learn more about Steve Crowley and his interviews with top companies.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) was also recently interviewed on
Investorideas.com in a Q&A format. Stephen M. Simes, President and CEO of BPAX Discusses
LibiGel (Testosterone Gel) in Phase III and GVAX Pancreas Vaccine in Phase II. The transcript is
available in full at: http://www.investorideas.com/CO/BPAX/news/11051.asp.

The company was also featured in a recent Investor Spotlight on Investordieas.com and its
syndicated partner sites:

BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® - testosterone gel for
the treatment of female sexual dysfunction

Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up to $5
billion

Point Roberts, WA, LINCOLNSHIRE, Ill - November 9, 2010 (Investorideas.com Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.

Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.

Highlights from the LibiGel Brochure:

Read the Full Brochure at: http://www.biosantepharma.com/libigel/LibiGel-Brochure.pdf

LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers

testosterone to the bloodstream evenly over time.

Full Article: http://www.investorideas.com/CO/BPAX/news/11101.asp

Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.

If you have any questions regarding information in this press release please contact the company
listed in the press release.

Contact BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com

or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316

azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://
www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of
Investorideas.com or related websites.

Disclaimer:
The following news is paid for by BPAX (three thousand per month) Investorideas.com is a
third party publisher of news and research .Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site
is currently compensated by featured companies, news submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com

Monday, November 15, 2010

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Third Quarter 2010 Financial Results

LINCOLNSHIRE, Ill. - November 15, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its third quarter 2010 financial results.
BioSante incurred a net loss of approximately $11.6 million or ($0.16) per share for the quarter ended September 30, 2010, compared to a net loss of $6.4 million or ($0.21) per share for the same period in 2009. This increase in net loss was primarily due to increased LibiGel clinical development expenses.
The Company's cash and cash equivalents as of September 30, 2010 were approximately $35.5 million, as compared to cash and cash equivalents of approximately $29.9 million on December 31, 2009. In October 2010, the Company received $244,479, the maximum per project, after LibiGel qualified for a grant under the Qualifying Therapeutic Discovery Project Program which was created in March 2010 as part of the Patient Protection and Affordability Care Act.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
For more information, please contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Friday, November 12, 2010

Biotech Stocks Trading Alert ; (OTCBB:UVFT), (NASDAQ:JAZZ), (OTCBB:AVXL) Stocks to Watch

Point Roberts, WA –November 12, 2010 (Investorideas.com Newswire and
www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for
investors, features a Biotech /Pharma trading alert featuring Biotech stocks trading up in today’s
trading. With overall markets off, Spectrum Pharmaceuticals, Inc , Anavex Life Sciences Corp.,
and UV Flu Technologies Inc are trading in the green.

Biotech /Pharma Sector Trading Snapshot: (as of time of release November 12th)

UV Flu Technologies, Inc. (OTCBB: UVFT) trading at $0.2825, up 0.0025 (0.89%)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading at $4.58, up 0.16 (3.62%)
Anavex Life Sciences Corp. (OTCBB: AVXL) trading at $4.25, up 0.03 (0.71%)

Market Summary (at time of release)
Dow 11,178.39 -104.71 -0.93%
NASDAQ 2,518.20 -37.32 -1.46%
S&P 500 1,197.62 -15.92 -1.31%
10 Yr Bond(%) 2.7310% +0.0830
Oil 84.85 -2.96 -3.37%
Gold 1,362.50 -40.60 -2.89%

Biotech/Pharma Stocks Recent News;

UV Flu Technologies, Inc. (OTCBB: UVFT) News:
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) ViraTech UV-400
Featured This Weekend on Nationally Televised Designing Spaces "Holiday Spaces" Show

CENTERVILLE, MA – November 10, 2010 (Investorideas.com Newswire) - UV Flu Technologies,
Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company's ViraTech UV-
400 air purifier technology is featured during "Designing Spaces-Innovations for a Healthy Home
this Holiday Season," scheduled to air on Women's Entertainment (WeTV) this Friday, November
12th, at 9:30 am, EST, and again at the same hour on Sunday the 14th and Monday the 15th.

"I was very excited to participate on the show, particularly with Dr. Dennis Rosen, a Director
of our Company and one of the foremost Pediatricians in the country today, as well as a
real advocate for issues affecting children's health," said Jack Lennon, President of UV Flu
Technology. "We hope to educate the public on the dangers associated with poor indoor air
quality at every opportunity, as we believe it contributes to tens of thousands of deaths and
billions of dollars of health care and lost work expenditures every year. We also wanted to inform
and educate the public of the hazards posed though the use of existing filter based products on
the market today that can cause serious illness if the filters or the electrostatic plates are not
changed or cleaned on a constant basis."
Full Article: http://www.investorideas.com/CO/UVFT/news/11101.asp

About Anavex Life Sciences Corp, (OTCBB: AVXL):
Anavex Life Sciences Corp. (www.anavex.com) is a biopharmaceutical company engaged in the
discovery and development of novel drug candidates for the treatment of neurological diseases
and cancer. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves
the rational design of drug compounds that are targeted to specific receptors involved in the
modulation of multiple cellular biochemical signaling pathways.

ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drug candidates

that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy,
depression, pain). The company's lead drug candidates exhibit high affinity for sigma receptors,
which have been extensively documented as potentially valuable drug targets and have
demonstrated anti-amnesic and neuroprotective properties.
Anavex is a publically traded company under the symbol "AVXL".

About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and
drug development operations with a primary focus in oncology. The Company’s strategy is
comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-
stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV
and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along
with a diversified pipeline of novel drug candidates. The Company has assembled an integrated
in-house scientific team, including clinical development, medical research, regulatory affairs,
biostatistics and data management, formulation development, and has established a commercial
infrastructure for the marketing of its drug products. The Company also leverages the expertise of
its worldwide partners to assist in the execution of its strategy. For more information, please visit
the Company’s website at www.sppirx.com.

Research other biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires
.

Sign up for free stock alerts on biotech stocks and other leading sectors!

http://www.investorideas.com/Resources/Newsletter.asp

More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com

About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the
biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research
the latest news, articles, audio, research reports and our stock directories.

Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX
(three thousand per month BPAX) Investorideas.com is a third party publisher of news and
research .Our sites do not make recommendations, but offer information portals to research
news, articles, stock lists and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment involves risk and possible
loss of principal. This site is currently compensated by featured companies, news submissions
and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

NASDAQ Biotech/Pharma Stock Watch ; (NASDAQ:BPAX), (NASDAQ:MNKD), (NASDAQ:SPPI)

Point Roberts, WA –November 12, 2010 (Investorideas.com Newswire and
www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools
for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the
NASDAQ’s market performers for the week. In todays down markets, Spectrum Pharmaceuticals,
Inc and Jazz Pharmaceuticals, Inc are in the green.

Biotech /Pharma Sector Trading Snapshot: (as of time of release November 12th)

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading at $4.5899, up 0.1699 (3.84%)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.56
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) trading at $ 15.15, up 0.03 (0.20%)

Market Summary (at time of release)

Dow 11,172.60 -110.50 -0.98%
NASDAQ 2,515.66 -39.86 -1.56%
S&P 500 1,197.46 -16.08 -1.33%
10 Yr Bond (%) 2.7450% +0.0970
Oil 84.89 -2.92 -3.33%
Gold 1,387.70 -15.40 -1.10%

Biotech/Pharma Stocks Recent News;

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:

Investor Spotlight on BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® -
testosterone gel for the treatment of female sexual dysfunction
Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up
to $5 billion

Point Roberts, WA, LINCOLNSHIRE, Ill –November 9, 2010 (Investorideas.com Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.

Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.

Highlights from the LibiGel Brochure:
Read the Full Brochure at: http://www.biosantepharma.com/libigel/LibiGel-Brochure.pdf

LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers
testosterone to the bloodstream evenly over time.
Full Article: http://www.investorideas.com/CO/BPAX/news/11101.asp

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) News:

“Jazz Pharmaceuticals, Inc. announced today that Bruce Cozadd, the company's chairman and
chief executive officer, will present at the Lazard Capital Markets Healthcare Conference in New
York on Wednesday, November 17, 2010 at 9:00 a.m. Eastern Time.

A live webcast of the presentation may be accessed from the Investors section of the Jazz
Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior
to the start of the conference call to ensure adequate time for any software downloads that may
be necessary to listen to the webcast.”

Full Article: http://finance.yahoo.com/news/Jazz-Pharmaceuticals-prnews-
3715707836.html?x=0&.v=1

About Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ):
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and
commercializes innovative treatments for important, underserved markets in neurology and
psychiatry. For further information see www.jazzpharmaceuticals.com.

About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and
drug development operations with a primary focus in oncology. The Company’s strategy is
comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-
stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV
and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along
with a diversified pipeline of novel drug candidates. The Company has assembled an integrated
in-house scientific team, including clinical development, medical research, regulatory affairs,
biostatistics and data management, formulation development, and has established a commercial
infrastructure for the marketing of its drug products. The Company also leverages the expertise of
its worldwide partners to assist in the execution of its strategy. For more information, please visit
the Company’s website at www.sppirx.com.

Research other biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires
.

Sign up for free stock alerts on biotech stocks and other leading sectors!

http://www.investorideas.com/Resources/Newsletter.asp

More news - Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com

About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the
biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research
the latest news, articles, audio, research reports and our stock directories.

Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX

(three thousand per month BPAX) Investorideas.com is a third party publisher of news and
research .Our sites do not make recommendations, but offer information portals to research
news, articles, stock lists and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment involves risk and possible
loss of principal. This site is currently compensated by featured companies, news submissions
and online advertising.
More info:
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Thursday, November 11, 2010

Biotech Stock Trading Alert; UV Flu Technologies (OTCBB: UVFT) Trading up on News

Point Roberts, WA. – November 11, 2010 (Investorideas.com Newswire) - www.InvestorIdeas.com and its leading Biotech investor portal, announces a technical stock trading alert and stock chart for showcase Biotech company UV Flu Technologies (OTCBB: UVFT).
Stock Chart for UVFT.OB
UV Flu Technologies (OTCBB: UVFT) Recent News:
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Announces UV-400 Air Purifier Delivers Favorable Preliminary Test Results for the Inactivation of Viruses
CENTERVILLE, MA – November 11, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has received favorable preliminary test results from an independent, FDA and EPA certified test facility that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol.
"These results, although preliminary, are highly encouraging," said Jack Lennon, President of UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over all three speeds, which was shown to be even higher at the four hour mark. We must emphasize that these results, although very positive, are only preliminary, but appear comparable to our previous results during the laboratory testing of the inactivation of bacteria. Our Company is firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by reputable agencies within certified facilities." More: http://www.investorideas.com/CO/UVFT/news/11111.asp
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at: http://www.investorideas.com/CO/UVFT/
Research Report by Michael Williams, Biotech Stock Pick: www.biotechstockpick.com
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at: www.uvflutech.com
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
http://www.investorideas.com/Resources/Newsletter.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory:
http://www.investorideas.com/BIS/Stock_List.asp

Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
For Additional Information about Investorideas.com energy portals: 800-665-0411 or cvanzant@investorideas.com

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Announces UV-400 Air Purifier Delivers Favorable Preliminary Test Results for the Inactivation of Viruses

CENTERVILLE, MA � November 11, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the Company has received favorable preliminary test results from an independent, FDA and EPA certified test facility that demonstrated the ViraTech UV-400 air purifier to be effective in the inactivation of a typical virus surrogate utilized as part of the test protocol.
"These results, although preliminary, are highly encouraging," said Jack Lennon, President of UV Flu Technologies. "The viral phage was tested multiple times, with the UV-400 running at three different speeds; low, medium and high, over a four hour period in a 430 cubic foot test chamber. After three hours, the chamber showed a sample inactivation rate of at least 99% over all three speeds, which was shown to be even higher at the four hour mark. We must emphasize that these results, although very positive, are only preliminary, but appear comparable to our previous results during the laboratory testing of the inactivation of bacteria. Our Company is firmly committed to supporting all claims with actual, verifiable laboratory testing undertaken by reputable agencies within certified facilities."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Wednesday, November 10, 2010

Investor Spotlight on BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® - testosterone gel for the treatment of female sexual dysfunction

Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up to $5 billion

Point Roberts, WA, LINCOLNSHIRE, Ill - November 9, 2010 (Investorideas.com Newswire) Investor ideas and its biotech portal present a company and product spotlight for B ioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.
Investors following biotech and pharmaceutical stocks can take an in-depth look at the current status of LibiGel®, the clinical data, the market drivers and opportunities within the company product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and CEO discussing LibiGel.
Highlights from the LibiGel Brochure:
Read the Full Brochure at: http://www.investorideas.com/CO/BPAX/news/LibiGel-Brochure-102910.pdf
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p < 0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
Therapeutic Indication
Hypoactive Sexual Desire Disorder (HSDD) � lack of sexual desire � affects millions of women in the U.S., especially those past menopause, whether natural or surgical. Studies find it is more common than erectile dysfunction � which is a $2 billion a year prescription business in the U.S. A University of Chicago study of 1,700 men and 1,700 women between the ages of 18 and 59 published in JAMA, found that 43% of women said they have experienced some degree of sexual dysfunction, compared with just 31% of men. Among the women surveyed, 32% lacked interest in sex. Further, according to a study published in the NEJM, 43% of women between the ages of 57 and 85 experience some degree of low sexual desire. The majority of women with FSD are postmenopausal, experiencing FSD due to hormonal changes following menopause, whether natural or surgical. In 2009, there were over 4.0 million testosterone prescriptions written off-label for the treatment of HSDD. Over 90% of women using testosterone off-label would be switched to LibiGel® once approved, according to surveyed physicians.
Unmet Clinical Need / Market Opportunity
The goal of testosterone treatment of women experiencing Hypoactive Sexual Desire Disorder (HSDD) is to increase the serum testosterone towards the normal range of premenopausal women in an effort to alleviate the symptoms of this disorder....
This market has wide potential with predictions ranging from about $2.0 billion up to $5 billion. The $2.0 billion potential is the size of the male market if one considers only the current erectile dysfunction products. The current market for testosterone products for men is approximately $1 billion and growing.
Results of Phase II for LibiGel Testing:
Specifically to testosterone and LibiGel in the treatment of female sexual dysfunction, there is little question that testosterone can increase the number of satisfying sexual events, the FDA�s primary endpoint for approval of a drug for this indication. Both BioSante and Proctor & Gamble (for their testosterone patch, Intrinsa, which is not currently in active clinical development and now owned by Warner Chilcott) have completed clinical trials showing the efficacy of testosterone to statistically and clinically significantly increase the number of satisfying sexual events.
Progress and Plans in Phase III:
Currently, BioSante is conducting three Phase III clinical studies to demonstrate the safety and efficacy of LibiGel to increase sexual desire and satisfying sexual events and to decrease distress associated with the decreased desire. Two Phase III safety and efficacy trials that are underway are randomized, doubleblind, placebo-controlled trials which will enroll approximately 500 surgically menopausal women each for six-months of treatment. BioSante is conducting these trials under an FDA agreed special protocol assessment (SPA). In addition, BioSante has another SPA agreement with the FDA related to treatment of naturally menopausal women. The SPA process and agreement confirms the FDA�s position that FSD and HSDD are true conditions that women experience, with measurable endpoints, that can be evaluated and which deserve therapeutic options. It also affirms that the FDA agrees that the LibiGel Phase III safety and efficacy clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses are acceptable to support regulatory approval. Further, it provides assurance that these agreed measures will serve as the basis for regulatory review and the decision by the FDA to approve an NDA for LibiGel....
In addition to the two Phase III safety and efficacy trials covered by the SPA, BioSante is conducting one Phase III cardiovascular and breast cancer safety study of LibiGel, which also is underway....
- BioSante�s objective is to submit the LibiGel NDA in 2011 for a potential FDA approval in 2012.
Recent News for LibiGel Product:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)  reports recent news; “BioSante Pharmaceuticals Reports Positive LibiGel ® Data Monitoring Committee Recommendation
Recent Q&A featuring LibiGel®
Q&A Interview with BioSante Pharmaceuticals (NASDAQ: BPAX), Update on LibiGel® (testosterone gel) for the treatment of female sexual dysfunction and its Pancreatic Cancer Vaccine
Stephen M. Simes, President and CEO Discusses LibiGel (testosterone gel) in Phase III and GVAX Pancreas Vaccine in Phase II
Full interview � read here: http://www.investorideas.com/CO/BPAX/news/11021.asp
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
This e-mail may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include statements about BioSante�s plans, objectives, expectations and intentions with respect to future operations and products, future market acceptance, size and potential of LibiGel and other statements identified by words such as �will,� �potential,� �could,� �would,� �can,� �believe,� �intends,� �continue,� �plans,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante�s actual results to be materially different than those expressed in or implied by BioSante�s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante�s licensees or sublicensees; the success of clinical testing; and BioSante�s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante�s actual results are described in BioSante�s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this presentation speak only as of the date of this presentation. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact BioSante:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The full BPAX company profile is available at http://www.investorideas.com/CO/BPAX/ for interested biotech investors.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/libigel/LibiGel-Brochure.pdf are not the opinion of Investorideas.com or related websites.
Please read the forward looking statements on BPAX news and website.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com